AIForbes Innovation2 days ago
Pfizer And Eli Lilly Partner With Chai Discovery On AI Antibody Models
1 min read
Chai Discovery's Chai-3 antibody AI model is being used by Pfizer and Eli Lilly to design novel therapeutics. The startup has secured a $400 million funding round at a $3.4 billion valuation. Chai-3 enables faster, more precise antibody design for drug discovery. The partnerships aim to reduce drug development time and costs from over 10 years and $1 billion to shorter, more targeted timelines.
Level
Hype check
Tap to vote and see what everyone thinks.
